A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
Launched by BIONTECH SE · Feb 7, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the flu vaccine and the COVID-19 vaccine work in healthy people, both when given alone and when mixed together. The goal is to understand how these vaccines act, which can help improve vaccination strategies in the future. The study is looking for healthy adults aged 18 and older to participate.
If you decide to join, you will receive one shot in your arm—either the flu vaccine, the COVID-19 vaccine, or a combination of both. You will need to visit the study site at least four times over about six months. To be eligible, you should be in good health and not have received any flu or COVID-19 vaccines in the past 150 days, nor any antiviral treatments for flu recently. If this sounds like something you’re interested in, please reach out for more details!
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Participants 18 years of age or older
- • Healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgement of the investigator to be eligible for inclusion in the study
- Exclusion criteria:
- • Vaccination with any investigational or licensed influenza vaccine within 150 days of enrollment
- • Vaccination with any investigational or licensed COVID 19 vaccine within 150 days of enrollment.
- • Receipt of antiviral therapies for influenza (eg, Tamiflu) within 180 days prior to Day 1.
- • Refer to the study contact for further eligibility details
About Biontech Se
BioNTech SE is a leading biotechnology company headquartered in Mainz, Germany, specializing in the development of innovative immunotherapies for the treatment of cancer and infectious diseases. Founded in 2008, BioNTech leverages its proprietary mRNA technology platform to create personalized therapies and vaccines, with a strong focus on scientific excellence and clinical advancement. The company gained worldwide recognition for its groundbreaking COVID-19 vaccine, developed in collaboration with Pfizer, demonstrating its commitment to addressing urgent global health challenges. With a robust pipeline of candidates in various stages of development, BioNTech is dedicated to transforming the landscape of medicine through cutting-edge research and strategic partnerships.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Walnut Creek, California, United States
Charlottesville, Virginia, United States
Honolulu, Hawaii, United States
Stockbridge, Georgia, United States
Milford, Connecticut, United States
Salt Lake City, Utah, United States
Anaheim, California, United States
Salt Lake City, Utah, United States
Miami, Florida, United States
San Diego, California, United States
Chesterfield, Missouri, United States
North Charleston, South Carolina, United States
Mesquite, Texas, United States
Riverside, California, United States
Nashville, Tennessee, United States
Tomball, Texas, United States
Hialeah, Florida, United States
Coral Gables, Florida, United States
North Las Vegas, Nevada, United States
Wilmington, North Carolina, United States
Philadelphia, Pennsylvania, United States
Columbus, Ohio, United States
Miami Lakes, Florida, United States
Houston, Texas, United States
Lake Forest, California, United States
East Syracuse, New York, United States
Brownsville, Texas, United States
Seattle, Washington, United States
Knoxville, Tennessee, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported